Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$296.85
+2.2%
$281.37
$253.30
$346.85
$159.62B0.492.84 million shs2.29 million shs
Biogen Inc. stock logo
BIIB
Biogen
$133.19
+2.4%
$126.09
$110.04
$238.00
$19.52B0.141.43 million shs1.47 million shs
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$108.26
+0.7%
$102.94
$76.53
$131.49
$26.02B1.29940,523 shs998,480 shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$111.51
-0.2%
$106.65
$66.01
$119.96
$138.71B0.297.68 million shs5.99 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$30.28
+5.5%
$26.52
$23.15
$129.39
$11.71B1.858.65 million shs14.69 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
+4.05%+4.70%+1.22%-4.97%-6.59%
Biogen Inc. stock logo
BIIB
Biogen
+3.57%+2.98%-0.79%-0.95%-43.88%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
+0.98%+2.30%+12.33%+15.21%+36.38%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+0.78%+4.23%+1.25%-0.14%+62.78%
Moderna, Inc. stock logo
MRNA
Moderna
+3.99%+7.05%+8.02%+3.50%-75.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amgen Inc. stock logo
AMGN
Amgen
4.3262 of 5 stars
2.22.03.33.93.92.50.6
Biogen Inc. stock logo
BIIB
Biogen
4.9602 of 5 stars
4.25.00.03.73.31.72.5
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.4867 of 5 stars
4.42.00.00.01.80.80.0
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4.8387 of 5 stars
1.43.04.24.14.02.53.1
Moderna, Inc. stock logo
MRNA
Moderna
4.3556 of 5 stars
4.02.00.04.61.22.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.35
Hold$307.823.69% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.38
Hold$188.4841.51% Upside
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.83
Moderate Buy$137.8627.34% Upside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.78
Moderate Buy$110.55-0.86% Downside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$46.6153.93% Upside

Current Analyst Ratings Breakdown

Latest AMGN, GILD, MRNA, BIIB, and BNTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Amgen Inc. stock logo
AMGN
Amgen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$328.00
6/26/2025
Biogen Inc. stock logo
BIIB
Biogen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$187.00
6/25/2025
Biogen Inc. stock logo
BIIB
Biogen
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$205.00 ➝ $213.00
6/25/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$138.00
6/24/2025
Amgen Inc. stock logo
AMGN
Amgen
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
6/24/2025
Amgen Inc. stock logo
AMGN
Amgen
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$305.00
6/16/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$145.00 ➝ $138.00
6/12/2025
Biogen Inc. stock logo
BIIB
Biogen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$115.00
6/12/2025
Biogen Inc. stock logo
BIIB
Biogen
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$121.00
6/12/2025
Biogen Inc. stock logo
BIIB
Biogen
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
6/5/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$134.00 ➝ $145.00
(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$33.42B4.78$32.30 per share9.19$10.93 per share27.16
Biogen Inc. stock logo
BIIB
Biogen
$9.68B2.02$24.53 per share5.43$114.71 per share1.16
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$2.98B8.74N/AN/A$87.61 per share1.24
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$28.75B4.82$6.91 per share16.14$15.44 per share7.22
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.62N/AN/A$28.33 per share1.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$4.09B$10.9627.0813.882.5317.39%176.11%12.39%8/5/2025 (Estimated)
Biogen Inc. stock logo
BIIB
Biogen
$1.63B$10.1313.158.071.0015.07%14.03%8.32%7/30/2025 (Estimated)
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$719.92M-$3.40N/AN/AN/A-27.37%-3.94%-3.41%8/4/2025 (Estimated)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$480M$4.7523.4813.750.7220.76%51.93%17.40%8/6/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-105.67%-28.69%-21.94%7/30/2025 (Estimated)

Latest AMGN, GILD, MRNA, BIIB, and BNTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
Amgen Inc. stock logo
AMGN
Amgen
$4.18$4.90+$0.72$3.20$8.05 billion$8.15 billion
5/1/2025Q1 2025
Biogen Inc. stock logo
BIIB
Biogen
$3.26$3.02-$0.24$1.64$2.25 billion$2.43 billion
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
4/24/2025Q1 2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.77$1.81+$0.04$1.04$6.77 billion$6.67 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$9.523.21%N/A86.86%14 Years
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.162.83%N/A66.53%10 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest AMGN, GILD, MRNA, BIIB, and BNTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.793%6/13/20256/13/20256/27/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
8.70
1.17
0.88
Biogen Inc. stock logo
BIIB
Biogen
0.27
1.44
1.01
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
10.18
10.02
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.16
1.37
1.23
Moderna, Inc. stock logo
MRNA
Moderna
N/A
4.22
4.14

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.69%
Biogen Inc. stock logo
BIIB
Biogen
0.18%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.27%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
28,000537.71 million534.00 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,605146.53 million146.26 millionOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
6,772240.39 million194.24 millionOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,6001.24 billion1.24 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800386.74 million344.20 millionOptionable

Recent News About These Companies

Moderna Stock Gains on Encouraging Flu Vaccine Data
Moderna flu vaccine shows superior results in phase 3 study
Moderna flu vaccine trial results clear path for combo shot
Moderna shines spotlight on new flu vaccine data
Moderna’s flu vaccine hits goal, paving way for combo shot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amgen stock logo

Amgen NASDAQ:AMGN

$296.85 +6.33 (+2.18%)
Closing price 04:00 PM Eastern
Extended Trading
$293.82 -3.03 (-1.02%)
As of 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen stock logo

Biogen NASDAQ:BIIB

$133.19 +3.12 (+2.40%)
Closing price 04:00 PM Eastern
Extended Trading
$133.61 +0.42 (+0.32%)
As of 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioNTech stock logo

BioNTech NASDAQ:BNTX

$108.26 +0.75 (+0.70%)
Closing price 04:00 PM Eastern
Extended Trading
$108.38 +0.11 (+0.11%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$111.51 -0.22 (-0.20%)
Closing price 04:00 PM Eastern
Extended Trading
$111.65 +0.14 (+0.13%)
As of 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$30.28 +1.59 (+5.54%)
Closing price 04:00 PM Eastern
Extended Trading
$30.36 +0.08 (+0.28%)
As of 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.